Why ARTV fell 30.0% on Oct 27 2026: clinical program halt
ARTV-30.0%on Tue Oct 27 2026
Artiva Biotherapeutics, Inc. Common Stock was down 30.0% on the day at $4.31, ranked #5 on 504× its usual five-minute volume, when TapeRank recorded this drop at 08:10 ET during the pre-market session.
THE DAY ON THE LIST · 1 EVENT
- 08:10 ETMOVER · PRE-MARKET
$4.31 · ▼ 30.0% ON THE DAY · 504× 5M RVOL · RANK #5
JUSTIFIEDCONFIDENCE5/5ARTV is down 29.9% after discontinuing AlloNK development, including cancellation of the planned Phase 3 trial, following fatal safety events and an FDA-requested enrollment pause. The 94% workforce reduction and strategic-alternatives review reinforce a fundamental setback that supports a severe repricing.
WHYA roughly 30% decline is proportionate to terminating the lead program after fatal safety events and abandoning Phase 3, rather than an outsized reaction to limited news.ANALYZED 07:56 ET · 14 MIN AGO · OPENAI/GPT-5.6-LUNATHE ROW AND SESSION LEVELS AT 08:10 ET
LAST4.31DAY▼ 30.0%5 MIN▼ 6.51%5M RVOL504×5M $VOL$501KFLOAT*48.9MRANK#5SESSIONPRE-MARKETVWAP4.51HOD4.97LOD4.07OR HIGH—OR LOW—PREV CLOSE6.16PM HIGH4.97PM LOW4.07GAP▼ 30.68% (indicated)* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO
THE SESSION
- 07:25 ETHalted (T1); resumed 07:50 ET, after 25 minutes
- 09:30 ETOpened at $4.25, -31.0% on the previous close of $6.16
- 09:59 ETRegular-session high, $4.45
- 10:11 ETRegular-session low, $4.00
- 15:59 ETLast trade of the regular session, $4.26, -30.8% on the previous close of $6.16
- Volume: 6.7M shares in regular hours, 1.5M before the open
ARTV opened at $4.25, well below the previous close of $6.16, briefly reached $4.45, then fell to $4.00 by 10:11 ET before recovering to finish the regular session at $4.26. TapeRank’s read tied the roughly 30% decline to Artiva discontinuing AlloNK development after fatal safety events and an FDA-requested enrollment pause, including cancellation of its planned Phase 3 trial; the company also planned to reduce its workforce by about 94%. The stock’s 07:25 ET halt resumed at 07:50 ET and followed the clinical-program news, while a separate halt-status update came after the regular-session close.
WRITTEN TUE OCT 27 2026 16:00 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE
FILINGS AND NEWS · 24H BEFORE THE MOVE
- 07:45 ETTrading Halt: Halt status updated at 7:45:00 AM ET: Quotation Resumption: News and Resumption TimesBenzinga
- 07:37 ETArtiva Biotherapeutics Cancels ACR Convergence 2026 Data Presentation And November 9 Investor Webcast Following AlloNK Development DiscontinuationBenzinga
- 07:36 ETArtiva Biotherapeutics To Reduce Workforce By ~94% Following Discontinuation Of AlloNK DevelopmentBenzinga
- 07:34 ETArtiva Biotherapeutics Halts Further Development Of AlloNK Following Fatal Safety Events And FDA-Requested Enrollment PauseBenzinga
- 07:25 ETTrading Halt: Halted at 7:25:00 a.m. ET - Trading Halt: Halt News PendingBenzinga
On the tape right now
WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY
Open the full list